XML 40 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenues (Tables)
 12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
Revenues consisted of the following (in thousands):
 Year Ended December 31,
 202120202019
Product revenues:
Gross product revenues$1,452,913 $962,591 $957,621 
Discounts and allowances(375,657)(221,041)(197,671)
Net product revenues1,077,256 741,550 759,950 
Collaboration revenues:
License revenues249,956 167,295 165,914 
Collaboration services revenues
107,758 78,693 41,911 
Total collaboration revenues357,714 245,988 207,825 
Total revenues$1,434,970 $987,538 $967,775 
Net product revenues by product were as follows (in thousands):
Year Ended December 31,
202120202019
CABOMETYX
$1,054,050 $718,687 $733,421 
COMETRIQ
23,206 22,863 26,529 
Net product revenues
$1,077,256 $741,550 $759,950 
Schedule of Concentration Risks
The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows:
 
Year Ended December 31,
 
202120202019
Ipsen Pharma SAS21 %15 %16 %
Affiliates of CVS Health Corporation14 %14 %15 %
Affiliates of McKesson Corporation14 %12 %12 %
Affiliates of AmerisourceBergen Corporation14 %11 %11 %
Affiliates of Optum Specialty Pharmacy8 %11 %13 %
As of December 31, 2021 and 2020, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows:
 
December 31,
 
20212020
Ipsen Pharma SAS50 %23 %
Affiliates of AmerisourceBergen Corporation11 %11 %
Affiliates of McKesson Corporation10 %12 %
Affiliates of CVS Health Corporation9 %11 %
Takeda Pharmaceutical Company Limited2 %10 %
Schedule of Revenues Disaggregated by Geographic Region
Total revenues by geographic region were as follows (in thousands):
Year Ended December 31,
202120202019
U.S.
$1,089,396 $752,890 $770,244 
Europe
302,073 151,631 152,771 
Japan
43,501 83,017 44,760 
Total revenues
$1,434,970 $987,538 $967,775 
Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances
The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):
Chargebacks, Discounts for Prompt Payment and Other
Other Customer Credits/Fees and Co-pay Assistance
Rebates
Total
Balance at December 31, 2019
$7,514 $3,497 $15,222 $26,233 
Provision related to sales made in:
Current period146,537 16,162 58,049 220,748 
Prior periods33 (352)612 293 
Payments and customer credits issued(144,231)(16,028)(56,479)(216,738)
Balance at December 31, 2020
9,853 3,279 17,404 30,536 
Provision related to sales made in:
Current period243,119 30,728 100,361 374,208 
Prior periods(64)(111)1,624 1,449 
Payments and customer credits issued(238,283)(25,021)(94,564)(357,868)
Balance at December 31, 2021
$14,625 $8,875 $24,825 $48,325 
Schedule of Other Assets and Other Liabilities
Contract assets and liabilities were as follows (in thousands):
 
December 31,
 
20212020
Contract assets(1)
$1,665 $— 
Contract liabilities:
Current portion(2)
$7,814 $1,790 
Long-term portion(3)
8,739 3,755 
Total contract liabilities$16,553 $5,545 
____________________
(1)    Presented in other long-term assets in the accompanying Consolidated Balance Sheets.
(2)    Presented in other current liabilities in the accompanying Consolidated Balance Sheets.
(3)    Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets.